There were 90 press releases posted in the last 24 hours and 154,986 in the last 365 days.

Nexien BioPharma and Ivy League University Medical School Collaborate On Pre-Clinical Cannabinoid Studies

Nexien Biopharma will investigate advanced cannabinoid-based formulations for acute treatment of convulsive disorders with an Ivy League Medical School.

Nexien Biopharma (OTCQB:NXEN)

By using our specific parenteral delivery system and advanced formulations, we hope to shorten the timeline for clinically significant treatment efficacy and symptom reduction.”
— Alex Wasyl, Chief Executive Officer of Nexien Biopharma Inc.
DENVER, COLORADO, UNITED STATES, November 28, 2018 / -- Nexien BioPharma And Ivy League University Medical School Collaborate On Pre-Clinical Cannabinoid Studies

Partnership Will Investigate Advanced Parenteral Cannabinoid-Based Formulations For Acute Treatment of Convulsive Disorders.

DENVER, Colo. (November 28, 2018): Nexien BioPharma Inc. (OTC QB: NXEN) (“Nexien” or the “Company”) announced it is initiating a collaboration with the University Medical School (the “Medical School”) to perform pre-clinical studies using advanced parenteral cannabinoid formulations developed by Nexien, known as NX01R1, NX01R2, and NX01R3 (“formulations”). These formulations target the alleviation of symptoms for the acute treatment and intervention of convulsive disorders and convulsive episodes.

Parenteral administration is a route of administration that includes intramuscular injections of the formulations for optimal dosing and bio-availabilty. Parenteral administration excludes oral administration of drug formulations.

Nexien will provide the Medical School’s Neurology Lab with specific formulations, in addition to a comprehensive study design developed by the Company’s scientific team. This pre-clinical research will be first performed in rodents, and will initially investigate the Maximum Tolerable Dose (“MTD”) Pharmacokinetic (“PK”) and Pharmacodynamic (“PD”) profiles of advanced cannabinoid-based parenteral formulations.

In November 2017, Nexien filed a provisional patent application with the United States Patent and Trademark Office (USPTO) relating to the use of cannabinoids to treat convulsive disorders, specifically epilepsy and refractory epilepsy. Refractory epilepsy is a form of epilepsy in which patients typically do not respond to existing available medications and treatment options.

“Nexien is very excited to be working with such a prestigious Medical School. Specifically, we’re working with the Neurology Department which is chaired by a renowned Epileptologist,” said Alex Wasyl, Chief Executive Officer of Nexien.

“A growing body of existing research performed on specific cannabinoids has shown impressive efficacy for treating targeted convulsive disorders, particularly those in which patients do not respond to currently available medications,” he said. “Nexien’s formulations address an intrinsic problem encountered when using cannabinoids to treat these indications. Cannabinoids intrinsically have very low oral bioavailability, and thus have significantly slower absorption into plasma and target tissues. By using our specific parenteral delivery system and advanced formulations, we hope to shorten the timeline for clinically significant treatment efficacy and symptom reduction compared with currently available cannabinoid-based medication for similar indications.”

About Convulsive Disorders & Refractory Epilepsy

A convulsion is a medical condition in which muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body. Because epileptic seizures typically include convulsions, the term convulsion is sometimes used as a synonym for seizure. However, not all epileptic seizures lead to convulsions, and not all convulsions are caused by epileptic seizures.

Refractory epilepsy means that medication options are not bringing a patient’s seizures under control. This condition might often be called by some other names, such as uncontrolled, intractable, or drug-resistant epilepsy. Refractory epilepsy is seen in adults and in children. About 1-in-3 people with epilepsy have what is considered refractory to some degree.

About Nexien BioPharma Inc.

Nexien BioPharma is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration (“FDA”) pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders.

Nexien BioPharma website:

Nexien Disclosure Notice: This press release may contain "forward-looking statements, which are deemed to be any statements made by or on behalf of Nexien BioPharma that are not statements of historical facts. These statements reflect current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this release, including the factors set forth in “Risk Factors” in our most recent Form 10-K filed with the Securities and Exchange Commission (SEC) and subsequent filings with the SEC. Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. Nexien BioPharma undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Company Contact:
Mark Lubchenco
Director of Investor Relations
Nexien BioPharma Inc.
Tel: 1-303-495-7583

PR Contact:
Drew White
NisonCo PR

Mark Lubchenco
Nexien BioPharma Inc
303 495 7583
email us here

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.